Belantamab mafodotin is a first-in-class B-cell receptor (BCMA) targeting antibody-drug conjugate (ADC) comprised of an anti-BCMA monoclonal antibody (mAb) and a potent potent payload that is linked to the mAb via a disulfide linker. This unique chemical design allows for potent BCMA-directed therapy with a low systemic exposure of the ADC payload, thus minimizing non-oncology toxicities and maximizing the potential to achieve synergistic effects in MM, thereby enhancing efficacy.

Belantamab mafodotin has demonstrated a potential to achieve synergistic effects in MM, thereby enhancing efficacy.

Belantamab mafodotin is a first-in-class B-cell receptor (BCMA) targeting antibody-drug conjugate (ADC) comprised of an anti-BCMA monoclonal antibody (mAb) and a potent payload that is linked to the mAb via a disulfide linker. This unique chemical design allows for potent BCMA-directed therapy with a low systemic exposure of the ADC payload, thus minimizing non-oncology toxicities and maximizing the potential to achieve synergistic effects in MM, thereby enhancing efficacy.

Belantamab mafodotin is a first-in-class B-cell receptor (BCMA) targeting antibody-drug conjugate (ADC) comprised of an anti-BCMA monoclonal antibody (mAb) and a potent payload that is linked to the mAb via a disulfide linker. This unique chemical design allows for potent BCMA-directed therapy with a low systemic exposure of the ADC payload, thus minimizing non-oncology toxicities and maximizing the potential to achieve synergistic effects in MM, thereby enhancing efficacy.

Belantamab mafodotin is a first-in-class B-cell receptor (BCMA) targeting antibody-drug conjugate (ADC) comprised of an anti-BCMA monoclonal antibody (mAb) and a potent payload that is linked to the mAb via a disulfide linker. This unique chemical design allows for potent BCMA-directed therapy with a low systemic exposure of the ADC payload, thus minimizing non-oncology toxicities and maximizing the potential to achieve synergistic effects in MM, thereby enhancing efficacy.

Belantamab mafodotin is a first-in-class B-cell receptor (BCMA) targeting antibody-drug conjugate (ADC) comprised of an anti-BCMA monoclonal antibody (mAb) and a potent payload that is linked to the mAb via a disulfide linker. This unique chemical design allows for potent BCMA-directed therapy with a low systemic exposure of the ADC payload, thus minimizing non-oncology toxicities and maximizing the potential to achieve synergistic effects in MM, thereby enhancing efficacy.

Belantamab mafodotin is a first-in-class B-cell receptor (BCMA) targeting antibody-drug conjugate (ADC) comprised of an anti-BCMA monoclonal antibody (mAb) and a potent payload that is linked to the mAb via a disulfide linker. This unique chemical design allows for potent BCMA-directed therapy with a low systemic exposure of the ADC payload, thus minimizing non-oncology toxicities and maximizing the potential to achieve synergistic effects in MM, thereby enhancing efficacy.

Belantamab mafodotin is a first-in-class B-cell receptor (BCMA) targeting antibody-drug conjugate (ADC) comprised of an anti-BCMA monoclonal antibody (mAb) and a potent payload that is linked to the mAb via a disulfide linker. This unique chemical design allows for potent BCMA-directed therapy with a low systemic exposure of the ADC payload, thus minimizing non-oncology toxicities and maximizing the potential to achieve synergistic effects in MM, thereby enhancing efficacy.

Belantamab mafodotin is a first-in-class B-cell receptor (BCMA) targeting antibody-drug conjugate (ADC) comprised of an anti-BCMA monoclonal antibody (mAb) and a potent payload that is linked to the mAb via a disulfide linker. This unique chemical design allows for potent BCMA-directed therapy with a low systemic exposure of the ADC payload, thus minimizing non-oncology toxicities and maximizing the potential to achieve synergistic effects in MM, thereby enhancing efficacy.

Belantamab mafodotin is a first-in-class B-cell receptor (BCMA) targeting antibody-drug conjugate (ADC) comprised of an anti-BCMA monoclonal antibody (mAb) and a potent payload that is linked to the mAb via a disulfide linker. This unique chemical design allows for potent BCMA-directed therapy with a low systemic exposure of the ADC payload, thus minimizing non-oncology toxicities and maximizing the potential to achieve synergistic effects in MM, thereby enhancing efficacy.

Belantamab mafodotin is a first-in-class B-cell receptor (BCMA) targeting antibody-drug conjugate (ADC) comprised of an anti-BCMA monoclonal antibody (mAb) and a potent payload that is linked to the mAb via a disulfide linker. This unique chemical design allows for potent BCMA-directed therapy with a low systemic exposure of the ADC payload, thus minimizing non-oncology toxicities and maximizing the potential to achieve synergistic effects in MM, thereby enhancing efficacy.

Belantamab mafodotin is a first-in-class B-cell receptor (BCMA) targeting antibody-drug conjugate (ADC) comprised of an anti-BCMA monoclonal antibody (mAb) and a potent payload that is linked to the mAb via a disulfide linker. This unique chemical design allows for potent BCMA-directed therapy with a low systemic exposure of the ADC payload, thus minimizing non-oncology toxicities and maximizing the potential to achieve synergistic effects in MM, thereby enhancing efficacy.

Belantamab mafodotin is a first-in-class B-cell receptor (BCMA) targeting antibody-drug conjugate (ADC) comprised of an anti-BCMA monoclonal antibody (mAb) and a potent payload that is linked to the mAb via a disulfide linker. This unique chemical design allows for potent BCMA-directed therapy with a low systemic exposure of the ADC payload, thus minimizing non-oncology toxicities and maximizing the potential to achieve synergistic effects in MM, thereby enhancing efficacy.

Belantamab mafodotin is a first-in-class B-cell receptor (BCMA) targeting antibody-drug conjugate (ADC) comprised of an anti-BCMA monoclonal antibody (mAb) and a potent payload that is linked to the mAb via a disulfide linker. This unique chemical design allows for potent BCMA-directed therapy with a low systemic exposure of the ADC payload, thus minimizing non-oncology toxicities and maximizing the potential to achieve synergistic effects in MM, thereby enhancing efficacy.

Belantamab mafodotin is a first-in-class B-cell receptor (BCMA) targeting antibody-drug conjugate (ADC) comprised of an anti-BCMA monoclonal antibody (mAb) and a potent payload that is linked to the mAb via a disulfide linker. This unique chemical design allows for potent BCMA-directed therapy with a low systemic exposure of the ADC payload, thus minimizing non-oncology toxicities and maximizing the potential to achieve synergistic effects in MM, thereby enhancing efficacy.

Belantamab mafodotin is a first-in-class B-cell receptor (BCMA) targeting antibody-drug conjugate (ADC) comprised of an anti-BCMA monoclonal antibody (mAb) and a potent payload that is linked to the mAb via a disulfide linker. This unique chemical design allows for potent BCMA-directed therapy with a low systemic exposure of the ADC payload, thus minimizing non-oncology toxicities and maximizing the potential to achieve synergistic effects in MM, thereby enhancing efficacy.

Belantamab mafodotin is a first-in-class B-cell receptor (BCMA) targeting antibody-drug conjugate (ADC) comprised of an anti-BCMA monoclonal antibody (mAb) and a potent payload that is linked to the mAb via a disulfide linker. This unique chemical design allows for potent BCMA-directed therapy with a low systemic exposure of the ADC payload, thus minimizing non-oncology toxicities and maximizing the potential to achieve synergistic effects in MM, thereby enhancing efficacy.

Belantamab mafodotin is a first-in-class B-cell receptor (BCMA) targeting antibody-drug conjugate (ADC) comprised of an anti-BCMA monoclonal antibody (mAb) and a potent payload that is linked to the mAb via a disulfide linker. This unique chemical design allows for potent BCMA-directed therapy with a low systemic exposure of the ADC payload, thus minimizing non-oncology toxicities and maximizing the potential to achieve synergistic effects in MM, thereby enhancing efficacy.

Belantamab mafodotin is a first-in-class B-cell receptor (BCMA) targeting antibody-drug conjugate (ADC) comprised of an anti-BCMA monoclonal antibody (mAb) and a potent payload that is linked to the mAb via a disulfide linker. This unique chemical design allows for potent BCMA-directed therapy with a low systemic exposure of the ADC payload, thus minimizing non-oncology toxicities and maximizing the potential to achieve synergistic effects in MM, thereby enhancing efficacy.

Belantamab mafodotin is a first-in-class B-cell receptor (BCMA) targeting antibody-drug conjugate (ADC) comprised of an anti-BCMA monoclonal antibody (mAb) and a potent payload that is linked to the mAb via a disulfide linker. This unique chemical design allows for potent BCMA-directed therapy with a low systemic exposure of the ADC payload, thus minimizing non-oncology toxicities and maximizing the potential to achieve synergistic effects in MM, thereby enhancing efficacy.

Belantamab mafodotin is a first-in-class B-cell receptor (BCMA) targeting antibody-drug conjugate (ADC) comprised of an anti-BCMA monoclonal antibody (mAb) and a potent payload that is linked to the mAb via a disulfide linker. This unique chemical design allows for potent BCMA-directed therapy with a low systemic exposure of the ADC payload, thus minimizing non-oncology toxicities and maximizing the potential to achieve synergistic effects in MM, thereby enhancing efficacy.

Belantamab mafodotin is a first-in-class B-cell receptor (BCMA) targeting antibody-drug conjugate (ADC) comprised of an anti-BCMA monoclonal antibody (mAb) and a potent payload that is linked to the mAb via a disulfide linker. This unique chemical design allows for potent BCMA-directed therapy with a low systemic exposure of the ADC payload, thus minimizing non-oncology toxicities and maximizing the potential to achieve synergistic effects in MM, thereby enhancing efficacy.

Belantamab mafodotin is a first-in-class B-cell receptor (BCMA) targeting antibody-drug conjugate (ADC) comprised of an anti-BCMA monoclonal antibody (mAb) and a potent payload that is linked to the mAb via a disulfide linker. This unique chemical design allows for potent BCMA-directed therapy with a low systemic exposure of the ADC payload, thus minimizing non-oncology toxicities and maximizing the potential to achieve synergistic effects in MM, thereby enhancing efficacy.

Belantamab mafodotin is a first-in-class B-cell receptor (BCMA) targeting antibody-drug conjugate (ADC) comprised of an anti-BCMA monoclonal antibody (mAb) and a potent payload that is linked to the mAb via a disulfide linker. This unique chemical design allows for potent BCMA-directed therapy with a low systemic exposure of the ADC payload, thus minimizing non-oncology toxicities and maximizing the potential to achieve synergistic effects in MM, thereby enhancing efficacy.

Belantamab mafodotin is a first-in-class B-cell receptor (BCMA) targeting antibody-drug conjugate (ADC) comprised of an anti-BCMA monoclonal antibody (mAb) and a potent payload that is linked to the mAb via a disulfide linker. This unique chemical design allows for potent BCMA-directed therapy with a low systemic exposure of the ADC payload, thus minimizing non-oncology toxicities and maximizing the potential to achieve synergistic effects in MM, thereby enhancing efficacy.

Belantamab mafodotin is a first-in-class B-cell receptor (BCMA) targeting antibody-drug conjugate (ADC) comprised of an anti-BCMA monoclonal antibody (mAb) and a potent payload that is linked to the mAb via a disulfide linker. This unique chemical design allows for potent BCMA-directed therapy with a low systemic exposure of the ADC payload, thus minimizing non-oncology toxicities and maximizing the potential to achieve synergistic effects in MM, thereby enhancing efficacy.

Belantamab mafodotin is a first-in-class B-cell receptor (BCMA) targeting antibody-drug conjugate (ADC) comprised of an anti-BCMA monoclonal antibody (mAb) and a potent payload that is linked to the mAb via a disulfide linker. This unique chemical design allows for potent BCMA-directed therapy with a low systemic exposure of the ADC payload, thus minimizing non-oncology toxicities and maximizing the potential to achieve synergistic effects in MM, thereby enhancing efficacy.